Use of 18F-PSMA-11 PET for Detection of Lesions in Iodine Refractory Thyroid Cancers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

8 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-01-24

Study Completion Date

2023-07-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Determine the diagnostic value of 18F-PSMA-11 in patients with iodine refractory thyroid cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of the 18F-PSMA Positron Emission Tomography (PET)/CT in Patients With Medullary Thyroid Cancer

NCT05534594

Medullary Thyroid Cancer Medullary Thyroid Carcinoma Thyroid Carcinoma, Medullary +1 more

COMPLETED NA

Evaluation of 18F-TFB PET/CT Scan in Patients With Differentiated Thyroid Cancer

NCT05575440

Differentiated Thyroid Gland Carcinoma Thyroid Gland Follicular Carcinoma Thyroid Gland Papillary Carcinoma

RECRUITING

Feasibility Study of Incorporating 18F-FDG-PET Imaging in Radiotherapy for Head and Neck Cancer

NCT00135161

Head and Neck Neoplasms

COMPLETED PHASE1

Clinical Evaluation of 18F-DOPA Positron Emission Tomography in Medullary Thyroid Cancer

NCT00647140

Thyroid Neoplasm Thyroid Carcinoma Medullary Carcinoma

TERMINATED PHASE2

Diagnostic Utility of [18F]-FDG-PET/CT and [124I]-PET/CT for Detection of Recurrence in Differentiated Thyroid Carcinoma

NCT01374659

Thyroid Cancer Recurrence

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Thyroid Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Overal Trial

only one arm in this trial

Group Type OTHER

PET/CT scan F18-PSMA-11

Intervention Type DIAGNOSTIC_TEST

PET/CT scan with F18-PSMA-11

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PET/CT scan F18-PSMA-11

PET/CT scan with F18-PSMA-11

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient is 18 years or older.
* Signed Informed Consent.
* Subject is diagnosed with a histologically confirmed differentiated thyroid carcinoma, that is considered RAI refractory. There is evidence of persisting or recurrent disease, based on serum thyroglobulin levels and/or medical imaging.
* Subject should have a routine clinical 18F-FDG PET/CT performed within two months prior to the study scan.
* Female patients should be either post-menopausal, surgically sterile, or using highly effective contraceptives (methods that can achieve a failure rate of less than 1%: combined hormonal contraception, progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomized partner, sexual abstinence).

Exclusion Criteria

* Patient has a known other active malignancy.
* Subject is potentially pregnant (urinary test can be performed in case of doubt) or breastfeeding.
* Patient is mentally or legally incapacitated.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No